Enhanced transmucosal composition and dosage form

Details Enhanced transmucosal composition and dosage form Enhanced transmucosal composition and dosage form

A - Human Necessities

61

K

A61K 9/00 (2006.01)

Patent

CA 2717984

The invention provides a transmucosal pharmaceutical composition comprising an active compound, a bile salt and an osmolality adjusting ingredient, wherein the osmolality adjusting ingredient generates a localized hyperosmotic environment and maintains an osmolality level for a period of time sufficient to produce hypertonicity- facilitated transmucosal transport of said active compound across the mucosal tissue. The invention also provides a solid transmucosal dosage form containing the composition, as well as a method of treatment comprising administering the same. In one embodiment, the active compound is a triptan compound, e.g., sumatriptan and zolmitriptan.

La présente invention concerne une composition pharmaceutique transmucosale comprenant un composé actif, un sel biliaire, et un ingrédient d'ajustement dosmolalité, lingrédient d'ajustement dosmolalité servant à générer un environnement hyperosmotique localisé et à maintenir un niveau dosmolalité pendant une période de temps suffisante pour produire un transport transmucosal facilité par hypertonie dudit composé actif à travers le tissu muqueux. La présente invention concerne également une forme pharmaceutique transmucosale solide contenant la composition, ainsi qu'un procédé de traitement comprenant l'administration de celle-ci. Dans un mode de réalisation, le composé actif est un composé de triptan, comme du sumatriptan et du zolmitriptan par exemple.

Affiliated with

Also associated with

Rating

Enhanced transmucosal composition and dosage form does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhanced transmucosal composition and dosage form, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced transmucosal composition and dosage form will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1654710